More than three years after Deciphera Pharmaceuticals’ first approval, the company appears to be on the precipice of achieving a second commercial product. Oral tumor treatment vimseltinib passed the ...

OSAKA, Japan & WALTHAM, Mass., November 17, 2025--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono ...

LAWRENCE, Kan.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, a clinical stage biotechnology company developing improved kinase inhibitor treatments for cancer, today announced that it has appointed ...

Ono Pharmaceutical is expanding its scope in oncology with a $2.4 billion deal to buy Deciphera Pharmaceutical, a company that has one commercialized cancer therapy and a drug pipeline that includes a ...

Deciphera Pharmaceuticals, Inc. DCPH announced that it has dosed the first patient in a phase I study which is evaluating its investigational ULK kinase inhibitor, DCC-3116, for the treatment of ...

Shares of Deciphera Pharmaceuticals, Inc. have rallied 40% since October after positive trial data for vimseltinib in the treatment of TGCT. Vimseltinib is expected to make significant progress in the ...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its first quarter 2021 financial results on Tuesday, May 4, 2021. In connection with ...

Deciphera Pharmaceuticals Inc DCPH announced top-line results from the MOTION Phase 3 study of vimseltinib in patients with Tenosynovial Giant Cell Tumor (TGCT) not amenable to surgery. The study met ...

Deciphera Pharmaceuticals, Inc. DCPH announced an outlook and planned corporate milestones for 2023. The company outlined certain commercial, clinical and preclinical activities for the year. Along ...

Deciphera Pharmaceuticals is stopping work on two programs, focusing its research efforts on two others, and cutting its headcount by 35% in a corporate restructuring. The moves announced Tuesday come ...